AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01049789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU - Treatment as Usual
Description: Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48.
Study NCT04450394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study NCT04450394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT01601093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose
Description: Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
Study NCT01601093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
Study NCT01601093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoperazone and Sulbactam Sodium (CFP/SUB)
Description: Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
Study NCT00948389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
Study NCT00948389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
Study NCT02389868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Study NCT00708344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan - Hydrochlorothiazide
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
Study NCT02885961 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: FDG PET scan
Description: Scan using PET combined with a high resolution CT scan (HRCT)
Study NCT03096158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AERO)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
Study NCT03096158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Training (ISO)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
Study NCT02204202 — intervention group
Intervention type: DRUG
Intervention: [18F]FDG
Description: 10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study NCT02204202 — intervention group
Intervention type: DRUG
Intervention: [18F]ISO-1
Description: 8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study NCT03748056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted incentives
Description: Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
Study NCT03748056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nominal loyalty card discount and nutrition education
Description: All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
Study NCT03748056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nominal loyalty card discount and nutrition education
Description: All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
Study NCT03299712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ArteFill
Description: soft tissue filler
Study NCT03514433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIP Patient Navigation Intervention
Description: The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
Study NCT04114110 — intervention group
Intervention type: OTHER
Intervention: RTLS data
Description: data extraction from RTLS
Study NCT00251251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy plus ICD
Description: ICD vs CRT/ICD
Study NCT00251251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy plus CRT/ICD
Description: ICD vs CRT/ICD
Study NCT00752726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Weight loss treatment
Study NCT00752726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study NCT03888209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
Study NCT03888209 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
Study NCT02939768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
Study NCT02939768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Description: ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
Study NCT04312425 — intervention group
Intervention type: PROCEDURE
Intervention: Modified rapid sequence induction
Description: Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
Study NCT04312425 — intervention group
Intervention type: PROCEDURE
Intervention: Classic rapid sequence induction
Description: In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
Study NCT00585793 — intervention group
Intervention type: DRUG
Intervention: NRTI/NNRTI/ Kaletra
Description: Fixed dose and cild formulation Kaletra
Study NCT01218048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
Study NCT03084887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manuals and follow-up
Description: distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
Study NCT02026687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study NCT02026687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal
Study NCT00836784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: old toothbrush
Description: All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
Study NCT00836784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New tooth brush
Description: The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes.
Study NCT00580892 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography imaging
Description: Optical Coherence Tomography imaging
Study NCT02939768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ST combined with HIIT (ST+HIIT)
Description: Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
Study NCT02447809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
Study NCT02447809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: (ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
Study NCT04152863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev IV
Description: Administered as an IV infusion of 1 X 10\^9 TCID50
Study NCT04152863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev ITu
Description: Administered as an ITu injection of 3 X 10\^8 TCID50
Study NCT04152863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion of 200 mg
Study NCT02447809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Study NCT02447809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Study NCT03534154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic Resonance Imaging
Study NCT03271684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management
Description: one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
Study NCT03271684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
Study NCT01639157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
Study NCT01639157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
Study NCT03534154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Sampling of serum
Study NCT03335514 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: expression of GALNT4
Description: Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
Study NCT03534154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microdialysis
Description: Monitoring of cerebral fluid protein levels
Study NCT03534154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Battery of tests to assess cognitive function, patient outcomes
Study NCT03534154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (advanced)
Description: Advanced MRI
Study NCT05162209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic
Description: Oral sachet, for 12 weeks
Study NCT05162209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Oral sachet, for 12 weeks
Study NCT02065232 — intervention group
Intervention type: DRUG
Intervention: Tilmanocept
Study NCT01461538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Study NCT01461538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 2.4 mg/kg every 3 weeks by intravenous (IV) infusion
Study NCT02065232 — intervention group
Intervention type: DRUG
Intervention: Sulfur Colloid
Study NCT04177602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil chemoradiation
Description: Trifluridine/tipiracil based chemoradiation
Study NCT04177602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine based chemoradiation
Description: Capecitabine based chemoradiation
Study NCT00471848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: 1.5 vials/10kg daily for 5 days
Study NCT03515772 — intervention group
Intervention type: DRUG
Intervention: Co-administration of darunavir with a cardiovascular drug
Description: Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
Study NCT00736008 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Data summary only
Study NCT00708344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan - Hydrochlorothiazide
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
Study NCT00074399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Tablet taken orally daily. Dosage depends on age and body surface area
Study NCT00074399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine placebo
Description: Placebo tablet taken orally daily
Study NCT00945945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (DLX)
Description: dose daily by mouth
Study NCT00945945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine (DLX)
Description: dose daily by mouth
Study NCT00945945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PLA)
Description: Placebo Comparator daily by mouth
Study NCT00945945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Placebo Comparator daily by mouth
Study NCT03655951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based resource on adolescent sexual health
Description: Web-based resource on adolescent sexual health than the intervention.
Study NCT03655951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate web-based resource on adolescent sexual health
Description: This is a different web-based resource on adolescent sexual health than the intervention.
Study NCT01549327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Interactive Navigator
Study NCT01549327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Study NCT01556581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
Study NCT01556581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Physical Therapy (PT)
Description: Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
Study NCT02081144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smokefree TXT Program
Description: The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
Study NCT02081144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement patches
Description: Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
Study NCT02081144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Gum
Description: Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
Study NCT02081144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faxed Referral CT Smokers Quitline
Description: A faxed referral will be sent to the CT Smokers Quitline for the subject.
Study NCT03647228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-ENaCRx
Description: Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
Study NCT03647228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator calculated volume to match active comparator inhaled or nebulized.
Study NCT01296256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine-EAM
Description: Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
Study NCT02291055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001
Study NCT02291055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study NCT04035161 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Investigational Product
Description: 2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
Study NCT04035161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference Standard
Description: 60% (v/v) 1-propanol skin preparation
Study NCT04035161 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: ChloraPrep® SEPP® skin preparation
Study NCT04035161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: 0.9% Normal Saline skin preparation
Study NCT01089439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide by inhalation INOMAX
Description: Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours
Study NCT01089439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02227342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: serial FMT
Study NCT03809520 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pedCAT
Description: Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.